Compare LMFA & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMFA | DRMA |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | 19 | 9 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.1M |
| IPO Year | 2015 | N/A |
| Metric | LMFA | DRMA |
|---|---|---|
| Price | $0.22 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 488.0K | 46.8K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.66 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,844,733.00 | N/A |
| Revenue This Year | $4.38 | N/A |
| Revenue Next Year | N/A | $650.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $0.59 |
| 52 Week High | $5.14 | $7.33 |
| Indicator | LMFA | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 43.93 |
| Support Level | $0.18 | $1.13 |
| Resistance Level | $0.27 | $1.40 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 5.36 | 23.21 |
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.